Chemically known as tirzepatide, Mounjaro is currently sold in the UK and Europe under the same brand name for both diabetes ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

Automated three-dimensional total-body photography improves the efficiency of positive malignant biopsies and reduces unnecessary biopsies of skin lesions, a study showed.

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class ...

Eli Lilly says it is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP and ...

Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Eli Lilly’s Mounjaro has launched in India. Approved by CDSCO, it promises significant weight loss and blood sugar control. However, concerns remain over certain side effects.

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...